Pre-clinical and Clinical Trails


Preclinical development, also known as preclinical studies and nonclinical studies, is a phase of drug development that starts before clinical trials (testing on humans) can start. It is during this phase that crucial feasibility, iterative testing, and drug safety data are gathered.



Determining the safe dose for the first-in-man study and evaluating a product's safety profile are the primary objectives of pre-clinical research. Products could include novel pharmaceuticals, medical devices, gene therapy treatments, and diagnostic equipment.



Only one out of every 5,000 molecules that start drug research and advance to the preclinical stage of development end up being authorized drugs.



 


    Related Conference of Pre-clinical and Clinical Trails

    November 27-28, 2025

    4th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland
    November 27-28, 2025

    4th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    December 01-02, 2025

    13th International Conference on Clinical Trials

    Vancouver, Canada
    January 29-30, 2026

    19th World Drug Delivery Summit

    Paris, France
    February 10-11, 2026

    40th World Congress on Pharmacology and Therapeutics

    Barcelona, Spain
    February 23-24, 2026

    3rd World Congress on Biologics and Biosimilars

    London, UK
    March 23-24, 2026

    36th Annual European Pharma Congress

    London, UK
    March 24-25, 2026

    11th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    April 16-17, 2026

    19th European Biosimilars Congress

    Rome, Italy
    April 27-28, 2026

    9th European Biopharma Congress

    Paris, Aland Islands
    May 28-29, 2026

    3rd International Conference on Pharmacognosy

    Madrid, Spain
    July 27-28, 2026

    39th World Congress on Pharmacology

    Rome, Italy

    Pre-clinical and Clinical Trails Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in